Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment DOI Creative Commons

Maryamosadat Mavaei,

Simin Farokhi,

Mohammad Hasan Yousefi

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: May 13, 2025

Cancer is a complex and heterogeneous disease that often requires multifaceted treatment strategies to achieve optimal therapeutic outcomes. Given the limitations of single-agent therapies, particularly in face intricate biological signaling networks resistance, there growing need for combinatory approaches. This article presents novel hypothesis: simultaneous use ribosome-inactivating proteins (RIPs) mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (EVs) cancer treatment. RIPs, with their potent cytotoxic properties, can target tumor effectively, while MSCs, known tumor-homing abilities regenerative potential, serve as delivery vehicles, potentially enhancing targeting precision reducing systemic toxicity RIPs. hypothesis explores synergistic potential combining these two modalities, leveraging advantages both techniques create more effective strategy. By RIPs’ ability inhibit protein synthesis MSCs EVs’ capability modulate microenvironment deliver agents. approach offers promising avenue overcoming cancer’s inherent complexity. However, challenges remain, such optimizing dosing protocols, addressing safety concerns, ensuring efficient drug delivery. Future research clinical trials are necessary validate this combination viable therapy.

Language: Английский

Exploring two tumor treatment strategies: effectiveness of ribosome inactivating proteins and mesenchymal stem cells/MSC derived extracellular vesicles in cancer treatment DOI Creative Commons

Maryamosadat Mavaei,

Simin Farokhi,

Mohammad Hasan Yousefi

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: May 13, 2025

Cancer is a complex and heterogeneous disease that often requires multifaceted treatment strategies to achieve optimal therapeutic outcomes. Given the limitations of single-agent therapies, particularly in face intricate biological signaling networks resistance, there growing need for combinatory approaches. This article presents novel hypothesis: simultaneous use ribosome-inactivating proteins (RIPs) mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (EVs) cancer treatment. RIPs, with their potent cytotoxic properties, can target tumor effectively, while MSCs, known tumor-homing abilities regenerative potential, serve as delivery vehicles, potentially enhancing targeting precision reducing systemic toxicity RIPs. hypothesis explores synergistic potential combining these two modalities, leveraging advantages both techniques create more effective strategy. By RIPs’ ability inhibit protein synthesis MSCs EVs’ capability modulate microenvironment deliver agents. approach offers promising avenue overcoming cancer’s inherent complexity. However, challenges remain, such optimizing dosing protocols, addressing safety concerns, ensuring efficient drug delivery. Future research clinical trials are necessary validate this combination viable therapy.

Language: Английский

Citations

0